Heparin calcium treated Henoch-Schönlein purpura nephritis in children through inhibiting hyperfibrinolysis.

Autor: Tian M; a Department of Kidney Rheumatology , Children's Hospital of Zhengzhou , Zhengzhou City , Henan Province , China., Liu C; a Department of Kidney Rheumatology , Children's Hospital of Zhengzhou , Zhengzhou City , Henan Province , China.
Jazyk: angličtina
Zdroj: Renal failure [Ren Fail] 2015 Aug; Vol. 37 (7), pp. 1100-4. Date of Electronic Publication: 2015 Jul 02.
DOI: 10.3109/0886022X.2015.1061668
Abstrakt: Aim: To explore the underlying mechanism of low-molecular-weight heparin calcium therapy on Henoch-Schönlein purpura nephritis (HSPN).
Methods: Eighty-nine children with severe HSPN were randomized into control group (treated with conventional therapy, n = 45) and treatment group (treated with conventional therapy plus low-molecular-weight heparin calcium, n = 44). The concentrations of plasma fibrinogen (Fg), d-dimer and fibrin degradation products (FDPs) were detected before and after treatment. The urinary red blood cell (RBC) and 24 h proteinuria were determined weekly for assessing the children's kidney function.
Results: Two groups were well-matched at baseline. After 8 weeks of treatment, the clinical outcomes of HSPN and outcome of proteinuria of the treatment group were better than the control group (p < 0.05); the content of Fg, d-dimer and FDP in plasma of the treatment group were lower than the control group (p < 0.05); but there was no difference about the curative effect of hematuria and the coagulation function between the two groups (p > 0.05).
Conclusions: Fibrinolytic system may participate in the kidney injury of HSPN children and low-molecular-weight heparin calcium could correct blood hypercoagulability through inhibiting hyperfibrinolysis, and thus improving the blood supply of kidney.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje